Brokers Set Expectations for ADAP Q1 Earnings

Adaptimmune Therapeutics plc (NASDAQ:ADAP) – Stock analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Adaptimmune Therapeutics in a research note issued on Tuesday, March 25th. Leerink Partnrs analyst J. Chang expects that the biotechnology company will post earnings per share of ($0.10) for the quarter. The consensus estimate for Adaptimmune Therapeutics’ current full-year earnings is ($0.14) per share. Leerink Partnrs also issued estimates for Adaptimmune Therapeutics’ Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.35) EPS and FY2026 earnings at ($0.11) EPS.

Adaptimmune Therapeutics (NASDAQ:ADAP) last posted its quarterly earnings data on Monday, March 24th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.09). The firm had revenue of $3.22 million for the quarter, compared to the consensus estimate of $16.56 million. Adaptimmune Therapeutics had a negative return on equity of 74.15% and a negative net margin of 25.43%.

ADAP has been the subject of several other research reports. Guggenheim reduced their target price on shares of Adaptimmune Therapeutics from $3.00 to $1.75 and set a “buy” rating for the company in a report on Wednesday. Wells Fargo & Company reduced their price objective on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an “equal weight” rating for the company in a research note on Friday, March 21st. Scotiabank lowered their target price on Adaptimmune Therapeutics from $3.15 to $1.40 and set a “sector outperform” rating on the stock in a research report on Friday, March 21st. Finally, StockNews.com assumed coverage on Adaptimmune Therapeutics in a report on Friday, March 21st. They set a “buy” rating on the stock. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $1.93.

Adaptimmune Therapeutics Price Performance

Shares of ADAP opened at $0.21 on Friday. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.62. Adaptimmune Therapeutics has a twelve month low of $0.20 and a twelve month high of $1.55. The stock has a market capitalization of $52.71 million, a P/E ratio of -0.94 and a beta of 2.52. The company has a 50 day moving average of $0.51 and a 200-day moving average of $0.67.

Institutional Investors Weigh In On Adaptimmune Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Invesco Ltd. raised its stake in Adaptimmune Therapeutics by 82.0% in the fourth quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company’s stock valued at $34,000 after buying an additional 28,526 shares during the period. Two Sigma Advisers LP boosted its stake in shares of Adaptimmune Therapeutics by 492.0% during the 4th quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company’s stock worth $38,000 after acquiring an additional 58,787 shares during the period. Two Sigma Investments LP increased its holdings in shares of Adaptimmune Therapeutics by 33.5% during the 4th quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 19,146 shares during the last quarter. Virtu Financial LLC raised its stake in Adaptimmune Therapeutics by 27.5% in the 3rd quarter. Virtu Financial LLC now owns 101,008 shares of the biotechnology company’s stock valued at $96,000 after acquiring an additional 21,769 shares during the period. Finally, Jane Street Group LLC lifted its holdings in Adaptimmune Therapeutics by 130.4% during the 3rd quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company’s stock valued at $166,000 after purchasing an additional 98,581 shares during the last quarter. 31.37% of the stock is owned by institutional investors.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.